MEDVi vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent research·How we rank →

MEDVi beats Willow overall, scoring 7.7/10 vs 7.5/10. MEDVi is more affordable at $179/mo vs $299/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Willow for users who want comprehensive clinical support with flexibili.

A side-by-side look at MEDVi and Willow to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Higher Rated

MEDVi

#20 of 52

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Willow

#24 of 52

7.5/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only, Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	MEDVi	Willow
Our Score	7.7/10	7.5/10
Starting Price	$179/mo	$299/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Users who want a low entry price with oral and injectable compounded options	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Ranking	#20	#24
Get started	Visit MEDVi	Visit Willow

Pros & Cons Compared

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide, one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only, no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses, starting dose is $399/mo
−Cash-pay only, no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024, less track record than Ro or Hims, though growth has been fast

Our Verdict

MEDVi edges out Willow with a score of 7.7/10 vs 7.5/10. If budget is your priority, MEDVi starts at $179/mo compared to Willow's $299/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

Still undecided? Editor's Featured Pick

Yucca Health

$146/mo · 7.7/10 · Compounded

If neither MEDVi nor Willow feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is Yucca Health. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $146/mo that stays the same at every dose.

Visit Yucca Health→Read our full Yucca Health review